Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study

Table 3 CD4+ count and high-sensitivity CRP pre-cART and longitudinally over 12 weeks, categorized by neuropathic symptom status

Variable	Time point	Time effect	Group effect
Variable	Time point	Median (IQR), pg/ml	Neuropathic symptom group Median (IQR)	Control group Median (IQR)
CD4+ count, cells/mm³	Baseline	141 (110; 189)	145 (109; 181)	138 (110; 194)
	Week 24	272 (204; 368)	298 (210; 457)	260 (179; 351)
hs-CRP, mg/L	Baseline	2.70 (0.90; 6.70)	2.90 (0.90; 6.70)	2.60 (0.90; 5.40)
	Week 2	6.70 (2.10; 18.50)	8.40 (3.40; 17.00)	5.30 (1.80; 19.30)
	Week 4	6.50 (3.30; 26.50)	8.40 (3.50; 30.60)	4.20 (3.30; 15.00)
	Week 12	3.95 (1.50; 7.20)	3.80 (1.50; 8.30)	4.20 (1.00; 6.70)

Incident neuropathic symptoms developed within 12 weeks of starting cART.
The control group refers to the symptom-free nested control group paired for previously identified risk factors.
Time effect: Bold numbers denote values different from baseline, p < 0.05.
Group effect: Bold numbers denote values different between groups compared to baseline, p < 0.05.
Abbreviations: IQR interquartile range, hs-CRP high-sensitivity C-reactive protein.

ISSN: 1471-2334